Introduction {#Sec1}
============

As key members of the innate immune response, natural killer (NK) cells survey surrounding cells, discriminating damaged or infected cells from healthy cells, in part via receptor recognition of altered self-MHC on damaged cells^[@CR1]^. This process, termed "education" or "licensing" is enabled through interactions between inhibitory receptors on NK cells with "self" MHC, that permit cytotoxic granule release for target cell killing, but also inhibition of the NK cell upon binding to cognate MHC. In humans, the principal receptors mediating education are the polygenic, polymorphic inhibitory killer cell immunoglobulin-like receptors (KIR), which recognize antigens presented by HLA-A, -B, and --C molecules^[@CR2]^.

The *KIR2DL* receptors exclusively recognize HLA-C molecules: *KIR2DL1* recognizes HLA-C allotypes characterized by Lys80 (collectively referred to as HLA-C group 2); *KIR2DL3* recognizes predominantly HLA-C allotypes characterized by Asn80 (HLA-C group 1); while *KIR2DL2* recognizes members of both HLA-C groups 1 and 2^[@CR2]^. Between the *KIR2DL* receptors and their specificities, nearly all HLA-C allotypes have a cognate inhibitory KIR. Additional inhibitory KIR molecules include KIR3DL1, which recognizes the Bw4 epitope exhibited by some HLA-A and HLA-B allotypes, and KIR3DL2, which recognizes the HLA-A3, HLA-A11, and HLA-B27 proteins^[@CR2],[@CR3]^.

Significant diversity exists from individual to individual both at the *KIR* gene content and allele level. Some patterns of genetic combination are well-recognized and have led to the designation of the canonical *KIR* haplotype-A, characterized by gene content as presence of the centromeric *KIR2DL3* and *KIR2DL1* and the telomeric *KIR3DL1*, in the absence of all activating *KIR*, with the exception of the telomeric *KIR2DS4*. The remaining haplotypes collectively comprise the *KIR* B-haplotypes, exhibiting differing numbers and types of activating *KIR* in the centromeric or telomeric portions^[@CR4]--[@CR6]^. Clinical consequences of *KIR* diversity, even at the level of gene content, have provided some clues to the importance of differentially educated NK cells in control of viral infection, such as hepatitis C^[@CR7]^, HIV^[@CR8]^ and hematologic malignancy^[@CR9],[@CR10]^.

Allelic polymorphism further diversifies the educational breadth of the NK repertoire. It is increasingly clear that different alleles of the same receptor, *KIR3DL1*, exhibit different surface expression properties and affinities for the same HLA ligand^[@CR11]--[@CR13]^, leading to substantial variations in NK education and sensitivity to inhibition^[@CR11],[@CR12]^. These findings have enabled a more intricate understanding of NK education, again with important implications in viral control^[@CR11],[@CR14]^ and malignancy^[@CR15]^. Whether allele subtype variation for KIR2DL similarly impacts NK cell function and disease outcomes has not been extensively studied. However, it is known that the KIR2DL receptors are highly polymorphic, and that allelic variation may influence cell surface expression^[@CR16],[@CR17]^, as well as avidity and specificity for HLA-C ligands^[@CR18],[@CR19]^, potentially leading to benefits in infectious disease^[@CR7],[@CR20]^.

While the clinical ramifications of allele-driven *KIR* diversity continue to emerge, a lack of straightforward technology to discriminate *KIR* content at the allele level has hampered large-scale clinical studies. Next-generation sequencing technology for *KIR* allele typing remains investigational^[@CR21]^ or out of practical reach for research laboratories. We previously reported an accessible multiplex PCR assay for the cost-effective discrimination of *KIR3DL1* alleles, and we have employed this assay in a large retrospective analysis of hematopoietic cell transplantation patients to demonstrate the clinical impact of functional *KIR* subtyping^[@CR15],[@CR22]^. We now present a similar approach for the centromeric inhibitory KIR genes *KIR2DL1*, *KIR2DL2*, and *KIR2DL3*, identifying the nucleotide sites potentially important for functional discrimination among receptor alleles and devising an amplification-refractory mutation system (ARMS) PCR-SSP typing methodology. We anticipate that functional classification of the centromeric inhibitory *KIR*, as has been done from the telomeric *KIR3DL1/S1*, will broaden our understanding of how these alleles influence human health and disease.

Results {#Sec2}
=======

*KIR2DL1* allele typing {#Sec3}
-----------------------

We examined the *KIR* alleles previously identified by sequence-based typing in a cohort of 426 healthy individual donors^[@CR23]^. Of the 34 known *KIR2DL1 alleles* (EMBL-EBI IPD KIR), four *(\*001, \*002, \*003*, \*004) occurred frequently, with a presence for each allele in 18% or more of the individuals in the cohort (Fig. [1A](#Fig1){ref-type="fig"}). Five other alleles *(\*007, \*008, \*009, \*020, \*021*) were found in fewer than 1% of all individuals. The remaining alleles were not identified in the cohort. Allelic distribution and phylogenetic analysis (Supplemental Fig. [1A](#MOESM1){ref-type="media"}) identified six non-overlapping groups. Six distinct ARMS PCR reactions specific for these six groups and four supplemental reactions to further discriminate alleles present within the group (Table [1](#Tab1){ref-type="table"}) were optimized using DNA from 178 of the original 426 donors. We designed an additional reaction to identify the pseudogene *KIR3DP1* and its variants (*KIR3DP1V*), the latter characterized by the presence of an exon 2. The presence of *KIR3DP1V* on the chromosome 19 is associated with the absence of *KIR2DL1* on the same haplotype^[@CR5],[@CR24],[@CR25]^. Detection of *KIR3DP1* and *KIR3DP1V* can therefore be used to estimate *KIR2DL1* copy number.Table 1KIR2DL PCR primers and target site positions.ReactionPrimers nameNucleotide targetedSequence PrimersSize amplicon (bp)ControlControlFNACCAAGCCCAACCTTAAGAAGAAAATTGGAG813ControlRNACCAAACCCACGGTACGCATGGGAACACTGC2DL1 Reaction 12DL1R1F3680AGAGATAAGACACCAGGAAGGGGAAGCCCG3882DL1R1R4011TGTCCAGAGGGTCACTGGGAGCTGACTC2DL1 Reaction 22DL1R2F5499GAGAGAGAGAGAGAGAGAGCATTAGGTCATAGTA3832DL1R2R5820TGACTTTGACCACTCGTATGGAGAGTCTT2DL1 Reaction 32DL1R3F13420ATCCTCTTCATCCTCCTCTTCTTTCTCCTTCACT2522DL1R3R13609CAGTTCAGAATCAGGCAACGGTCTGTGAAT2DL1 Reaction 42DL1R4F5499GAGAGAGAGAGAGAGAGAGCATTAGGTCATAGGA2972DL1R4R5735TGGCCTGGAATGTTCCGTTGACCTTGCT2DL1 Reaction 52DL1R5F3790AACCTTCCCTCCTGGCCCACCCAGGTAC2782DL1R5R4011GATGTCCAGAGGGTCACTGGGAGCTGACGC2DL1 Reaction 62DL1R6F5616ATATGAGAAACCTTCTCTCTCAGCCCAGTT2022DL1R6R5761GTGGGTGGCAGGGCCCAGAGGAAAGTAA2DL1 Reaction 73DP1FNAACGTGTTGTGAGTTGGTCATAGTGA6493DP1VFNAAAGTGGAAATGGGAGAATCTTCTGAC3823DP1RNAGCCCTCTGACCTGTGACCATGATC2DL1 Optional 12DL1O1F71GTTGGTCATAGTGAAGGACACTAGGTGTCAAATTCTATC2742DL1O1R281TCACCAACACACGCCATGCTGACGTC2DL1 Optional 22DL1O2F281CTCCGGCAGCACCATGTCGCTCTTAT3902DL1O2R620CCGTAACTCCACCTCCAGGCCCATTA2DL1 Optional 32DL1O3F3787AAACCTTCCCTCCTGGCCCACCCAAA3762DL1O3R4110CTTCCTTACAGCCACCTGGGTCTCCAGT2DL1 Optional 42DL1O4F3942GGGTCTCCAAGGCCAACTTCTCCATGG2222DL1O4R4110CTTCCTTACAGCCACCTGGGTCTCCACT2DL2 Reaction 12DL2R1F5663TATCCAGGGAGGGGGAGGCCCATGATT2112DL2R1R5820TGAGACAGATATGGGGTTTCCTCACCAG2DL2 Reaction 22DL2R2F5663TATCCAGGGAGGGGGAGGCCCATGATT2102DL2R2R5820GAGACAGATATGGGGTTTCCTCACCCA2DL2 Reaction 32DL2R3F13995ACAGATGCTGCGGTAATGGACCAAGATT3092DL2R3R14249ATCTGGACTCAGCATTTGGAAGTTCCCC2DL2 Reaction 42DL2R4F11984CTACTTCCAATCACCTGTGGAGATTCATG23222DL2R4R14249ATCTGGACTCAGCATTTGGAAGTTCCTT2DL2 Optional 12DL2O1F3754AACCTTCCCTCCTGGCCCACCCAGGTTC1912DL2O1R3890CATCATGGGACCGATGGAGAAGTTGGTT2DL2 Optional 22DL2O2F3754AACCTTCCCTCCTGGCCCACCCAGGTAG1912DL2O2R3890CATCATGGGACCGATGGAGAAGTTGGGT2DL3 Reaction 12DL3R1F13892ATGAAATGAGGGCCCAGAAGTGCCCTGT3142DL3R1R14154GGTGTCTTGGGCCTCTGAGAAGGAC2DL3 Reaction 22DL3R2F3825CACAGAGAAGGGAAGTTTAAGGACACTTTGTG3992DL3R2R4168TGTATGGCCCCTGTGTCTGTCCTTT2DL3 Reaction 32DL3R3F9063CTGTCTCATGTTCTAGGAAACCCTTCAAATAGTTGGGT3192DL3R3R9303GAAGGATGTCAGATTGGCAATCATTCTTCTAGCTTGTAGGAAA2DL3 Reaction 42DL3R4F13973GCCTGCAGGGAACAGAACAGTGAACAAG2332DL3R4R14154GGTGTCTTGGGCCTCTGAGAAGGCT2DL3 Reaction 52DL3R5F3853CCTCATTGGAGAGCACCATGATGGGGCT4302DL3R5R4222CCTCTCTCTGGGACATGTCTGTCTGTCTGTCTGT2DL3 Optional 12DL3O1F3708TAGGAGTCCACAGAAAACCTTCCCTCGG3232DL3O1R3976GAATGTCCGGACACTCTCACCTGTGACG2DL3 Optional 22DL3O2F16795CCCTCCATCTGGGTGCTTGTCCTAAAGGCG2132DL3O2R16949GCGATGAAGGAGAAAGAAGAGGAGGAGGTC2DL3 Optional 32DL3O3F17646TGAACAAGACCCTCAGGAGGTGACATTT1692DL3O3R17761TCATGGGCAGGAGACAACTTTGGATAT2DL3 Optional 42DL3O4F7315TCCTGCAATGTTGGTCAGATGTCAGGTTCG6432DL3O4R7903AGGCCACAGGGCCCAACTCAGGTCGT2DL3 Optional 52DL3O5F13892ATGAAATGAGGGCCCAGAAGTGCCCTGT2782DL3O5R14111CTCTGTGTGAAAACGCAGTGATTCAACTGTTT2DL3 Optional 62DL3O6F13892ATGAAATGAGGGCCCAGAAGTGCCCTGT2782DL3O6R14111CTCTGTGTGAAAACGCAGTGATTCAACTGTTC

Altogether, by using all eleven PCR reactions, we were able to separate ten different individual alleles or groups of alleles (*KIR2DL1*-*G\*001, -G\*002, -G\*003, -G\*004, -G\*012, \*006, \*008, \*010, \*011, \*020*) exhibited individually or in combination (Supplemental Fig. [2A,B](#MOESM1){ref-type="media"}). A few combinations of alleles, involving *KIR2DL1*-*G\*012* in particular, cannot be resolved with our method (Fig. [1B](#Fig1){ref-type="fig"}). It should be noted that these alleles are rare, and none of them was found in the 426 sequenced individuals.Figure 1*KIR2DL1* allele typing method. (**A**) Alignment of the amino acid sequences of the 34 known *KIR2DL1* allelic variants. A dash indicates identity with the consensus *KIR2DL1\*003*, and an (\*) indicates a stop codon. Structural domains are indicated: Ig-like domains (D1 and D2), stem domain (ST), transmembrane domain (TM), and cytoplasmic domain (CYT). Six PCR reactions separate the six subgroups identified by phylogenetic analysis. Four additional PCR reactions separate alleles within subgroups. Frequencies of the alleles present in the learning cohort of 426 individuals and in the testing cohort of 260 individuals are indicated. The group identification number for each allele is indicated. Alleles identified by PCR are in bold black font, and alleles that were not tested are in gray italics. (**B**) *KIR2DL1* PCR interpretation guide. PCR profiles marked by \*, \#, or \$ are similar and require a higher resolution of genotyping using supplemental reactions.

*KIR2DL2* allele typing {#Sec4}
-----------------------

Among the 13 *KIR2DL2* alleles published in EMBL-EBI IPD KIR database, only three alleles *(\*001, \*003, \*005*) occur in our cohort of 426 healthy individuals (Fig. [2A](#Fig2){ref-type="fig"}). Phylogenetic analysis suggests that these three alleles typify separate functional groups (Supplemental Fig. [1B](#MOESM1){ref-type="media"}). Four ARMS PCR reactions define the three groups, and two supplemental reactions increase the resolution of the method (Table [1](#Tab1){ref-type="table"}). With this approach, we can separate six different individual alleles or groups of alleles (*KIR2DL2*-*G\*001, -G\*003, -G\*005, \*004, \*006, \*009*) (Supplemental Fig. [2C,D](#MOESM1){ref-type="media"}).Figure 2*KIR2DL2* allele typing method. (**A**) Alignment of the amino acid sequences of the 13 known *KIR2DL2* allelic variants. A dash indicates identity with the consensus *KIR2DL2\*003*. Structural domains are indicated: Ig-like domains (D1 and D2), stem domain (ST), transmembrane domain (TM), and cytoplasmic domain (CYT). Four PCR reactions separate the three subgroups identified by phylogenetic analysis. Two additional PCR reactions separate alleles within subgroups. Frequencies of the alleles present in the learning cohort of 426 individuals and in the testing cohort of 260 individuals are indicated. The group identification of each allele is indicated. The alleles tested by PCR are in bold black font, and non-tested alleles are in gray italics. (**B**) *KIR2DL2* PCR interpretation guide. PCR profiles marked by \*, \#, \$ or & are similar and require a higher resolution of genotyping using supplemental reactions.

All *KIR2DL2* reactions were optimized using DNA from 178 of the 426 healthy donors. Previously reported analysis of these same DNA samples could not completely resolve *KIR2DL2\*005* from *KIR2DL2\*001*^[@CR23]^. With our method, we did not identify the presence of *KIR2DL2\*005* and instead found that 21 of the 21 samples with ambiguous typing exhibited *KIR2DL2\*001*. The presence of *KIR2DL2\*001* and the absence of *KIR2DL2\*005* in these samples were confirmed by sequencing by an independent laboratory (data not shown). Figure [2A](#Fig2){ref-type="fig"} displays the amino acid alignment of *KIR2DL2* alleles and segregation of alleles by the typing methodology. Ambiguity in interpretation for certain combinations of alleles occurs, as indicated (Fig. [2B](#Fig2){ref-type="fig"}).

*KIR2DL3* allele typing {#Sec5}
-----------------------

Of 34 *KIR2DL3* alleles published in an EMBL-EBI IPD *KIR* database, only five *(\*001, \*002, \*003, \*005, \*006*) were identified in the cohort of 426 healthy individuals (Fig. [3A](#Fig3){ref-type="fig"}). Phylogenetic analysis (Supplemental Fig. [1C](#MOESM1){ref-type="media"}) suggested four separate groups, which could be segregated by five distinct main ARMS PCR reactions (Fig. [3B](#Fig3){ref-type="fig"}), complemented by six supplemental reactions to further optimize resolution. With these eleven PCR reactions (Table [1](#Tab1){ref-type="table"}), we could separate eleven different alleles or groups of alleles (*KIR2DL3*-*G\*001, -G\*002, -G\*005, \*003, \*006, \*009, \*010, \*014, \*015, \*017, \*018*) (Supplemental Fig. [1E,F](#MOESM1){ref-type="media"}).Figure 3*KIR2DL3* allele typing method. (**A**) Alignment of the amino acid sequences of the 34 known *KIR2DL3* allelic variants. A dash indicates identity with the consensus *KIR2DL3\*001*, an (\*) indicates a stop codon. Structural domains are indicated: Ig-like domains (D1 and D2), stem domain (ST), transmembrane domain (TM), and cytoplasmic domain (CYT). Five PCR reactions separate the four subgroups identified by phylogenetic analysis. Six additional PCR reactions separate alleles within subgroups. Frequencies of the alleles present in the learning cohort of 426 individuals and in the testing cohort of 260 individuals are indicated. The group identification for each allele is indicated. The alleles tested by PCR are in bold black font, and the non-tested alleles are in gray italics. (**C**) *KIR2DL3* PCR interpretation guide. PCR profiles marked by \* or \# are similar and require a higher resolution of genotyping using supplemental reactions.

We confirmed accuracy of the typing methods for *KIR2DL1*, *KIR2DL2*, and *KIR2DL3* by comparing results using this methodology for 200 donors of the validation cohorts to results generated by another laboratory by a sequence-based typing methodology, finding 99.6% concordance^[@CR26],[@CR27]^.

Linkage disequilibrium between *KIR2DL* alleles {#Sec6}
-----------------------------------------------

We calculated LD between alleles of *KIR2DL1*, *KIR2DL2*, *KIR2DL3*, *KIR3DP1*, and the presence or absence of gene *KIR2DS2* in 260 individuals (Fig. [4A](#Fig4){ref-type="fig"}). Seven allele combinations, three belonging to the canonical centromeric haplotype-A (*KIR2DL1-KIR2DL3-KIR3DP1*)^[@CR23],[@CR28]^ and four belonging to the centromeric haplotype-B, were represented in more than 95% of the donors. Of interest, the centromeric haplotype-B allele combination comprised of *KIR2DL1\*004, KIR2DL2\*006* and the absence of *KIR2DS2* was found in 2.3% of individuals typed.Figure 4Linkage disequilibrium between KIR2DL alleles. (**A**) Linkage disequilibrium analysis identifies seven common combinations of centromeric *KIR2DL* alleles in a cohort of 260 individuals. (**B**) Allelic segregation of the *KIR2DL* and *KIR3DP1* alleles in CEPH families. Paternal *KIR2DL* alleles are shown in blue; maternal alleles in red. (**C**) *KIR2DL* allele typing from three generations of CEPH family individuals demonstrates Mendelian inheritance of allele combinations established by the LD study.

To confirm the LD observed by calculation in our cohort, we also genotyped immortalized B cell lines from the Centre d'Etude Polymorphisme Humaine (CEPH). We selected 5 families and performed *KIR2DL* allele typing using our methodology (Fig. [4B,C](#Fig4){ref-type="fig"}). The typing results demonstrated a Mendelian inheritance of allele combinations established by the LD study.

Discussion {#Sec7}
==========

We have established a comprehensive genotyping method to distinguish alleles and allele groups for the *KIRL2DL1*, *KIR2DL2* and *KIR2DL3* genes. We validated the methodology using 178 donors from a learning cohort and 260 samples from a validation cohort, further confirming its robustness by sequence-based typing. Designed as a typing kit for the centromeric region of the *KIR* haplotype, our methodology provides a reliable, cost-effective alternative to sequencing methods that can be employed using basic laboratory equipment.

The *KIR2DL1* typing method identifies the four most common *KIR2DL1* alleles, in addition to the less common *KIR2DL1\*006* and *KIR2DL1\*010* alleles found in three individuals. The learning cohort of 178 individuals was mostly comprised of Caucasian individuals, while the testing cohort was more ethnically diverse. For the 136 individuals in the testing cohort for whom we could obtain ethnicity, 59.6% were Caucasian,17.6% Asian, 16.2% African-American, 3.7% Hispanic, and 2.9% mixed ethnicity. Consistent with this population diversity, our typing revealed in several individuals the presence of *KIR2DL1\*006*, an allele previously reported to be relatively well-represented (7%) in an African-American cohort^[@CR29]^. With our *KIR2DL2* typing method, we can now faithfully resolve ambiguities between *KIR2DL2\*005* and *KIR2DL2\*001* reported with previous methodologies^[@CR23]^. A third typing methodology validated our results^[@CR26],[@CR27]^.

Copy number for the *KIR2DL1* alleles can be estimated using typing for the framework pseudogene *KIR3DP1*, where the *KIR3DP1V (\*001, \*002, \*004, \*007, \*009, \*011, \*012*) alleles are associated with the absence of *KIR2DL1*. Concerning *KIR2DL2* and *KIR2DL3*, copy number estimation was based on the mutual non-co-expression due to the allelic relationship of the two genes for the same locus. Our method has its limitations and is accurate for content only with copy number and haplotype inferred by LD. It has previously been reported that an additional *KIR2DL1*, *KIR2DL2* or *KIR2DL3* allele occurs in 1 to 2% of the population^[@CR30]^. To identify these individuals, a quantitative PCR assay would be informative in addition to our typing method to calculate more accurately copy number of each *KIR* allele^[@CR31]^.

The LD analysis identified the seven predominant combinations of *KIR2DL* receptors, representing more than 95% of the 260 donors studied. Genotyping of the CEPH family further validated the utility of our method and confirmed the Mendelian inheritance of the allele combinations established by the LD study.

This typing methodology will facilitate future studies aimed at determining if functional differences exist between alleles, as suggested by phylogenetic segregation. As has previously been demonstrated for the *KIR3DL1* alleles, diversity in cell surface expression, ligand affinity, and effector function for the *KIR2DL* alleles may combine to modulate NK education and influence innate immune response to viral pathogens and malignancy.

Methods {#Sec8}
=======

Genomic analyses and Primer design {#Sec9}
----------------------------------

All allele-coding sequences of *KIR2DL1, KIR2DL2* and *KIR2DL3* from the EMBL-EBI IPD KIR database sequences (<http://www.ebi.ac.uk/ipd/kir/alleles.html>) were included in our alignment analyses. We performed gene alignments and phylogenetic analyses using MacVector software version 13.5.5. Protein sequences of alleles for *KIR2DL1* (Supplemental Fig. [1A](#MOESM1){ref-type="media"}), *KIR2DL2* (Supplemental Fig. [1B](#MOESM1){ref-type="media"}) and *KIR2DL3* (Supplemental Fig. [1C](#MOESM1){ref-type="media"}) were aligned and analyzed by tree building methods: neighbor joining (Uncorrected method, Best Tree) with MacVector. Genomic sequencing in a cohort of 426 European-American healthy donors previously identified nine *KIR2DL1*, three *KIR2DL2* and five *KIR2DL3 alleles* respectively^[@CR23]^. Among *KIR2DL1*, *KIR2DL2*, and *KIR2DL3* alleles, four, three, and three alleles were found with \>1% frequency respectively. Sequence homology was then used in conjunction with the phylogenetic analyses to categorize alleles into *KIR* allele subgroups, for which PCR primer combinations were then designed. Low frequency alleles were assigned to subgroups based on sequence homology in the exon coding regions. Primer pairs targeting SNPs present in each subtype group were identified and their specificity for *KIR2DL1, KIR2DL2* or *KIR2DL3* was confirmed using NCBI primer blast. To provide an internal control for DNA quality, an 813 bp control band derived from a conserved region of the *APC* gene was multiplexed into each reaction. Specific primer sequences and PCR conditions are shown in Table [1](#Tab1){ref-type="table"}. The position of the SNP targeted is based on the following genomic sequences: for *KIR2DL1* primers *KIR2DL1\*00303* (IPD Acc No: KIR00005), for *KIR2DL2* primers *KIR2DL2\*0030101* (IPD Acc No: KIR00012), for *KIR2DL3* primers *KIR2DL3\*0010101* (IPD Acc No: KIR00014).

For *KIR2DL1*, we designed six PCR reactions to delineate six distinct allele groups based on the coding sequences and four supplemental reactions to identify additional subgroups or individual alleles represented in the n = 426 cohort (Fig. [1A](#Fig1){ref-type="fig"}). We designed one additional reaction for *KIR3DP1-3DP1V* to determine *KIR2DL1* copy number^[@CR5]^. For *KIR2DL2* alleles, we designed four PCR reactions to separate three distinct groups with two supplemental reactions to identify subgroups (Fig. [2A](#Fig2){ref-type="fig"}). For *KIR2DL3* alleles, five PCR reactions separate alleles into four distinct groups, with six supplemental reactions to identify some subgroups or individual alleles (Fig. [3A](#Fig3){ref-type="fig"}). The design of the primers was optimized using the software AmplifX (V1.7.0, <http://crn2m.univ-mrs.fr/pub/recherche/equipe-t-brue/jullien-nicolas/programmation/amplifx/>), following the principles of amplification refractory mutation system (ARMS)-PCR^[@CR32]^. All primers are ARMS-PCR primers, with the exceptions of the control primers and *KIR2DL1* allele primer pair \#7, and were designed for an annealing temperature of 63 °*C* (Table [1](#Tab1){ref-type="table"}). We used a testing cohort of 260 healthy individuals whose KIR genotypes had been identified by sequence-based typing to verify the specificity of the primers, as well as 178 DNA from the European-American healthy donors (Figs [1A](#Fig1){ref-type="fig"}--[3A](#Fig3){ref-type="fig"}).

PCR Reactions {#Sec10}
-------------

The ProFlex PCR system (Life Technologies) was used to optimize and validate the PCR reaction conditions. Each 20 µL reaction included 50--100 ng of DNA and was prepared with Taq polymerase (0.25 µL), dNTP (0.5 µL) and PCR buffer (2 µL) (Roche). Each primer was used at a final concentration of 0.5 µM. All reactions used the following PCR template: 95 °*C* 5 min, (95 °*C* 15 s, 63 °*C* 20 s, 72 °*C* 1 min) X 40 cycles, 72 °*C* 7 min, with the exception of 2DL2 PCR reaction \#4, which utilized the following conditions: 95 °*C* 5 min, (95 °*C* 15 s, 63 °*C* 20 s, 72 °*C* 2.5 min) X 40 cycles, 72 °*C* 7 min. (Control primers were designed to amplify a fragment of the *APC* gene. All reactions utilize reaction-specific primers and the control primers, except for *KIR2DL1* PCR reaction 7 and *KIR2DL2* PCR reaction 4, which do not include control primers. We analyzed all PCR products using electrophoresis on 1.5% agarose gels for 40 min at 125 V. Control bands (813 bp) confirmed DNA quality. Specific product sizes ranged from 0.2--2.3 kb (Table [1](#Tab1){ref-type="table"})

PCR interpretation {#Sec11}
------------------

The *KIR2DL1, KIR2DL2* and *KIR2DL3* PCR profiles are displayed respectively in Figs [1B](#Fig1){ref-type="fig"}--[3B](#Fig3){ref-type="fig"}. In cases where the observed results prompt multiple interpretations, supplemental reactions can be used to increase resolution. A few very rare allelic combinations cannot be discerned from each other and are indicated as ambiguous combinations in the table footnotes. Gel electrophoresis and interpretation of the basic and supplemental reactions for *KIR2DL1*, *KIR2DL2*, and *KIR2DL3* are shown in Supplemental Fig. [2](#MOESM1){ref-type="media"}.

Cells, DNA Sources and Preparation {#Sec12}
----------------------------------

Genomic DNA was extracted from cell lines, frozen peripheral blood mononuclear cells (PBMC) and whole blood using blood mini kits according to the manufacturer's instructions (Qiagen). EBV-immortalized cell lines derived from multi-generational families were produced by the Centre d'Etude Polymorphisme Humaine (CEPH) (<http://www.cephb.fr/en/familles_CEPH.php-presentation>). Samples were anonymized by the CEPH. DNA samples from unrelated hematopoietic stem cell donors were collected under National Marrow Donor Program (NMDP) Institutional Review Board-informed research consent and provided by the NMDP Research Repository. We collected PBMC from consenting healthy human donors at MKSCC and the New York Blood Center, following approval from the MSKCC Institutional Review Board. Additional PBMC were isolated from buffy coats obtained from healthy volunteer donors via the New York Blood Center (<http://nybloodcenter.org/>). The MSKCC IRB waived the need for additional research consent for anonymous NYBC samples.

Statistics {#Sec13}
----------

Linkage disequilibrium (LD) between pairs of *KIR* alleles was calculated according to Mattiuz *et al*.^[@CR33]^, and the significance of LD values was assessed by χ^2^ analysis.

Statement of Informed consent {#Sec14}
-----------------------------

All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all individual participants included in the study.
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